SES
24.2.2021 08:52:07 CET | Business Wire | Press release
SES, the leader in global content connectivity solutions, announced today that the Ethiosat platform is now broadcasting all channels of the Association of Ethiopian Broadcasters (AEB) and the Ethiopian Broadcasting Corporation (EBC) exclusively, including many of Ethiopia’s most popular channels such as EBS, ETV News and FANA TV. The variety of lifestyle, news, sport and educational channels – more than 90 channels, out of which 21 are in high definition (HD) – from 57 degrees East, offers unmatched quality and convenience previously not experienced by Ethiopians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006278/en/
In December 2020, the Ethiopian Government announced that all satellite TV channels should be moved to SES’s NSS-12 satellite so that Ethiosat can meet the local TV audiences’ desire for local and international news and entertainment channels while fuelling growth in the Ethiopian media sector.
Since then, the AEB and the EBC have had their members migrate their TV channels and broadcast them from one orbital position rather than have their viewers navigate through a multitude of foreign channels.
To support this migration, SES, through its established Elevate Installer Training programme, and supported by local partners Ethiopian Broadcasting Authority (EBA) and Ethiopian Science and Space Institution (ESSTI), has carried out daily training sessions. As a result, there are now 20,000 certified installers from all regions across Ethiopia who are equipped to help Ethiopian viewers repoint their dishes and continue to watch their favourite local channels without any disruption.
“Repointing dishes for millions of TV households across Ethiopia is not an easy feat, and it’s only possible when we have committed partners such as SES. It has taken us slightly less than two months to get our members’ channels moved to Ethiosat via SES’s satellite, and we are pleased with the progress of repointing the antennas so far,” said Amman Fissehazion, Chairman of AEB.
“We can proudly say that Ethiopians now have their own dedicated TV platform hosting exclusively all Ethiopian satellite TV channels,” said Dr Getachew Dinku Godana, Director General of EBA. “In addition to the high-quality content that this platform is offering, the strategic collaboration behind it has contributed to the creation of jobs and a sense of unity among the Ethiopian population.”
“Our commitment to our local partners in Ethiopia has never been stronger. In an incredibly short time frame, together with our local partners, we have managed to train 20,000 installers and have all AEB and EBC channels now broadcast exclusively from Ethiosat,” said Steve Collar, CEO at SES. “However, our work doesn’t stop here. Together with our local team based in Addis Ababa, we will continue to work with our local partners to repoint dishes across the country, while making sure that Ethiosat continues to host the most attractive TV offering comprising local and international channels.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Ethiosat
Ethiosat is Ethiopia’s first dedicated TV platform to host the most popular local channels. Ethiosat’s tagline “Colour Your World” is inspired by the colourfulness of Ethiopian culture and tradition. The logo is a representation of the fact that a dedicated platform has been created for Ethiopia via satellite. You can follow Ethiosat on social media: Facebook (@ethiosatTV), Instagram(@ethiosat) or Telegram (@EthiosaTV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006278/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom